

**Table S2** – Population of cats studied

	Pimobendan		Placebo		Total	
	N	%	N	%	N	%
<b>All randomized</b>	<b>44</b>	<b>100</b>	<b>39</b>	<b>100</b>	<b>83</b>	<b>100</b>
- with LVOTO	15	34	15	39	30	36
- without LVOTO	29	66	24	61	53	64
<b>SAF</b>	<b>43</b>	<b>100</b>	<b>39</b>	<b>100</b>	<b>82</b>	<b>100</b>
- with LVOTO	15	35	15	39	30	37
- without LVOTO	28	65	24	61	52	63
<b>FAS</b>	<b>39</b>	<b>100</b>	<b>37</b>	<b>100</b>	<b>76</b>	<b>100</b>
- with LVOTO	14	36	15	40	29	38
- without LVOTO	25	64	22	60	47	62
<b>PPS1</b>	<b>33</b>	<b>100</b>	<b>29</b>	<b>100</b>	<b>62</b>	<b>100</b>
- with LVOTO	11	33	13	45	24	39
- without LVOTO	22	67	16	55	38	61
<b>PPS2</b>	<b>30</b>	<b>100</b>	<b>29</b>	<b>100</b>	<b>59</b>	<b>100</b>
- with LVOTO	8	27	13	45	21	36
- without LVOTO	22	73	16	55	38	64

Abbreviations: N, number of cats; LVOTO, left ventricular outflow tract obstruction; SAF, safety analysis set population; FAS, full analysis set population; PPS1, per protocol set 1 population; PPS2, per protocol set 2 population.